Enfusion, Inc. (NYSE:ENFN) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lowered its position in shares of Enfusion, Inc. (NYSE:ENFN) by 19.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 40,740 shares of the company’s stock after selling 9,840 shares during the quarter. Alliancebernstein L.P.’s holdings in Enfusion were worth $420,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ENFN. Rhumbline Advisers lifted its stake in Enfusion by 3.0% during the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after purchasing an additional 1,796 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Enfusion by 3.3% in the 4th quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock worth $1,303,000 after buying an additional 4,032 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Enfusion by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock valued at $3,823,000 after buying an additional 5,639 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Enfusion during the 4th quarter valued at about $75,000. Finally, Quantbot Technologies LP acquired a new stake in Enfusion during the fourth quarter worth about $144,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Insider Buying and Selling at Enfusion

In other Enfusion news, CEO Oleg Movchan sold 2,790 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $32,029.20. Following the transaction, the chief executive officer now directly owns 643,299 shares in the company, valued at $7,385,072.52. This trade represents a 0.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bronwen Bastone sold 3,126 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $35,573.88. Following the completion of the sale, the insider now owns 221,875 shares of the company’s stock, valued at approximately $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,223 shares of company stock worth $754,778. 36.44% of the stock is currently owned by company insiders.

Enfusion Stock Down 0.0 %

ENFN opened at $10.80 on Monday. The business has a fifty day simple moving average of $11.08 and a 200-day simple moving average of $10.43. The firm has a market cap of $1.39 billion, a PE ratio of 269.94, a P/E/G ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Enfusion (NYSE:ENFN) last released its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. On average, equities research analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Analyst Ratings Changes

ENFN has been the topic of several recent research reports. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.